{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:54:02Z","timestamp":1791942842959,"version":"4.3.4"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AmyPore","award":["Private funding"],"award-info":[{"award-number":["Private funding"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-94148-1","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T09:52:58Z","timestamp":1742205178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Preclinical assessment of a ganglioside-targeted therapy for Parkinson\u2019s disease with the first-in-class adaptive peptide AmyP53"],"prefix":"10.1038","volume":"15","author":[{"given":"Jacques","family":"Fantini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fodil","family":"Azzaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Aulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Chahinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouara","family":"Yahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"issue":"6","key":"94148_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong, M. J. & Okun, M. S. Diagnosis and treatment of Parkinson disease: A review. Jama 323(6), 548\u2013560 (2020).","journal-title":"Jama"},{"issue":"s1","key":"94148_CR2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"E Dorsey","year":"2018","unstructured":"Dorsey, E. et al. The emerging evidence of the Parkinson pandemic. J. Parkinsons Dis. 8(s1), S3\u2013S8 (2018).","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"94148_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/mds.27063","volume":"33","author":"A Rossi","year":"2018","unstructured":"Rossi, A. et al. Projection of the prevalence of Parkinson\u2019s disease in the coming decades: Revisited. Mov. Disord. 33(1), 156\u2013159 (2018).","journal-title":"Mov. Disord."},{"issue":"7","key":"94148_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","volume":"20","author":"N Vijiaratnam","year":"2021","unstructured":"Vijiaratnam, N. et al. Progress towards therapies for disease modification in Parkinson\u2019s disease. Lancet Neurol. 20(7), 559\u2013572 (2021).","journal-title":"Lancet Neurol."},{"issue":"4","key":"94148_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3233\/JPD-239901","volume":"13","author":"K McFarthing","year":"2023","unstructured":"McFarthing, K. et al. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2023 update. J. Parkinsons Dis. 13(4), 427\u2013439 (2023).","journal-title":"J. Parkinsons Dis."},{"issue":"11","key":"94148_CR6","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/nrd.2018.136","volume":"17","author":"D Charvin","year":"2018","unstructured":"Charvin, D. et al. Therapeutic strategies for Parkinson disease: Beyond dopaminergic drugs. Nat. Rev. Drug Discov. 17(11), 804\u2013822 (2018).","journal-title":"Nat. Rev. Drug Discov"},{"issue":"4","key":"94148_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41582-019-0155-7","volume":"15","author":"A Elkouzi","year":"2019","unstructured":"Elkouzi, A. et al. Emerging therapies in Parkinson disease\u2014repurposed drugs and new approaches. Nat. Rev. Neurol. 15(4), 204\u2013223 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"94148_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fnmol.2019.00299","volume":"12","author":"CR Fields","year":"2019","unstructured":"Fields, C. R., Bengoa-Vergniory, N. & Wade-Martins, R. Targeting alpha-synuclein as a therapy for Parkinson\u2019s disease. Front. Mol. Neurosci. 12, 299 (2019).","journal-title":"Front. Mol. Neurosci."},{"key":"94148_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.expneurol.2017.10.003","volume":"298","author":"P Brundin","year":"2017","unstructured":"Brundin, P., Dave, K. D. & Kordower, J. H. Therapeutic approaches to target alpha-synuclein pathology. Exp. Neurol. 298, 225\u2013235 (2017).","journal-title":"Exp. Neurol."},{"key":"94148_CR10","doi-asserted-by":"publisher","first-page":"852003","DOI":"10.3389\/fneur.2022.852003","volume":"13","author":"S Menon","year":"2022","unstructured":"Menon, S. et al. Alpha-synuclein targeting therapeutics for Parkinson\u2019s disease and related synucleinopathies. Front. Neurol. 13, 852003 (2022).","journal-title":"Front. Neurol."},{"issue":"3","key":"94148_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3233\/JPD-171103","volume":"7","author":"C Galvagnion","year":"2017","unstructured":"Galvagnion, C. The role of lipids interacting with \u03b1-synuclein in the pathogenesis of Parkinson\u2019s disease. J. Parkinsons Dis. 7(3), 433\u2013450 (2017).","journal-title":"J. Parkinsons Dis."},{"issue":"8","key":"94148_CR12","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1523\/JNEUROSCI.08-08-02804.1988","volume":"8","author":"L Maroteaux","year":"1988","unstructured":"Maroteaux, L., Campanelli, J. T. & Scheller, R. H. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8(8), 2804\u20132815 (1988).","journal-title":"J. Neurosci."},{"issue":"5785","key":"94148_CR13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1126\/science.1129462","volume":"313","author":"AA Cooper","year":"2006","unstructured":"Cooper, A. A. et al. \u03b1-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson\u2019s models. Science 313(5785), 324\u2013328 (2006).","journal-title":"Science"},{"issue":"4","key":"94148_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3233\/JPD-150642","volume":"5","author":"J Burr\u00e9","year":"2015","unstructured":"Burr\u00e9, J. The synaptic function of \u03b1-synuclein. J. Parkinsons Dis. 5(4), 699\u2013713 (2015).","journal-title":"J. Parkinsons Dis."},{"issue":"4","key":"94148_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1517\/14728222.2012.674111","volume":"16","author":"K Vekrellis","year":"2012","unstructured":"Vekrellis, K. & Stefanis, L. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson\u2019s disease and other synucleinopathies. Expert Opin. Ther. Targets 16(4), 421\u2013432 (2012).","journal-title":"Expert Opin. Ther. Targets"},{"issue":"6","key":"94148_CR16","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/j.1742-4658.2012.08489.x","volume":"279","author":"IF Tsigelny","year":"2012","unstructured":"Tsigelny, I. F. et al. Role of \u03b1-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. Febs J. 279(6), 1000\u20131013 (2012).","journal-title":"Febs J."},{"issue":"8","key":"94148_CR17","doi-asserted-by":"publisher","first-page":"e42545","DOI":"10.1371\/journal.pone.0042545","volume":"7","author":"F Schmidt","year":"2012","unstructured":"Schmidt, F. et al. Single-channel electrophysiology reveals a distinct and uniform pore complex formed by \u03b1-synuclein oligomers in lipid membranes. PLoS One. 7(8), e42545 (2012).","journal-title":"PLoS One"},{"key":"94148_CR18","doi-asserted-by":"crossref","unstructured":"Yahi, N. et al. Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic \u03b1-synuclein oligomers in Parkinson\u2019s disease. Glycoconj. J. 1\u201311 (2021).","DOI":"10.1007\/s10719-021-10012-0"},{"issue":"30","key":"94148_CR19","doi-asserted-by":"publisher","first-page":"10427","DOI":"10.1073\/pnas.0502066102","volume":"102","author":"A Quist","year":"2005","unstructured":"Quist, A. et al. Amyloid ion channels: A common structural link for protein-misfolding disease. Proc. Natl. Acad. Sci. U. S. A. 102(30), 10427\u201310432 (2005).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6895","key":"94148_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/418291a","volume":"418","author":"HA Lashuel","year":"2002","unstructured":"Lashuel, H. A. et al. Neurodegenerative disease: Amyloid pores from pathogenic mutations. Nature 418(6895), 291 (2002).","journal-title":"Nature"},{"issue":"2","key":"94148_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/07391102.2003.10506918","volume":"21","author":"VN Uversky","year":"2003","unstructured":"Uversky, V. N. A protein-chameleon: Conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn. 21(2), 211\u2013234 (2003).","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"7\u20138","key":"94148_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10930-009-9201-4","volume":"28","author":"VN Uversky","year":"2009","unstructured":"Uversky, V. N. Intrinsically disordered proteins and their environment: Effects of strong denaturants, temperature, pH, counter ions, membranes, binding partners, osmolytes, and macromolecular crowding. Protein J. 28(7\u20138), 305\u2013325 (2009).","journal-title":"Protein J."},{"key":"94148_CR23","doi-asserted-by":"publisher","first-page":"p568068","DOI":"10.1155\/2010\/568068","volume":"2010","author":"VN Uversky","year":"2010","unstructured":"Uversky, V. N. The mysterious unfoldome: Structureless, underappreciated, yet vital part of any given proteome. J. Biomed. Biotechnol. 2010, 568068 (2010).","journal-title":"J. Biomed. Biotechnol."},{"issue":"7","key":"94148_CR24","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/febs.13202","volume":"282","author":"VN Uversky","year":"2015","unstructured":"Uversky, V. N. Functional roles of transiently and intrinsically disordered regions within proteins. FEBS J. 282(7), 1182\u20131189 (2015).","journal-title":"FEBS J."},{"key":"94148_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s12013-007-0014-9","volume":"47","author":"K Beyer","year":"2007","unstructured":"Beyer, K. Mechanistic aspects of Parkinson\u2019s disease: \u03b1-synuclein and the biomembrane. Cell Biochem. Biophys. 47, 285\u2013299 (2007).","journal-title":"Cell Biochem. Biophys."},{"key":"94148_CR26","doi-asserted-by":"crossref","unstructured":"Das, T. & Eliezer, D. Membrane interactions of intrinsically disordered proteins: The example of alpha-synuclein. Biochim. Biophys. Acta BBA Proteins Proteom. 1867(10), 879\u2013889 (2019).","DOI":"10.1016\/j.bbapap.2019.05.001"},{"issue":"4","key":"94148_CR27","doi-asserted-by":"publisher","first-page":"p140767","DOI":"10.1016\/j.bbapap.2022.140767","volume":"1870","author":"C Tempra","year":"2022","unstructured":"Tempra, C. et al. A unifying framework for amyloid-mediated membrane damage: The lipid-chaperone hypothesis. Biochim. Biophys. Acta BBA Proteins Proteom. 1870(4), p140767 (2022).","journal-title":"Biochim. Biophys. Acta BBA Proteins Proteom."},{"issue":"24","key":"94148_CR28","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1021\/acschemneuro.0c00588","volume":"11","author":"MF Sciacca","year":"2020","unstructured":"Sciacca, M. F. et al. Lipid-chaperone hypothesis: A common molecular mechanism of membrane disruption by intrinsically disordered proteins. ACS Chem. Neurosci. 11(24), 4336\u20134350 (2020).","journal-title":"ACS Chem. Neurosci."},{"key":"94148_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/bs.apcsb.2021.08.001","volume":"128","author":"BK Pathak","year":"2022","unstructured":"Pathak, B. K. et al. The role of membranes in function and dysfunction of intrinsically disordered amyloidogenic proteins. Adv. Protein Chem. Struct. Biol. 128, 397\u2013434 (2022).","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"94148_CR30","doi-asserted-by":"crossref","unstructured":"Fantini, J. Lipid Rafts and Human Diseases: Why We Need To Target Gangliosides (FEBS Open Bio, 2023).","DOI":"10.1002\/2211-5463.13612"},{"issue":"1","key":"94148_CR31","doi-asserted-by":"publisher","first-page":"27125","DOI":"10.1038\/srep27125","volume":"6","author":"G Fusco","year":"2016","unstructured":"Fusco, G. et al. Structural ensembles of membrane-bound \u03b1-synuclein reveal the molecular determinants of synaptic vesicle affinity. Sci. Rep. 6(1), 27125 (2016).","journal-title":"Sci. Rep."},{"issue":"4","key":"94148_CR32","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jmb.2011.03.009","volume":"408","author":"J Fantini","year":"2011","unstructured":"Fantini, J. & Yahi, N. Molecular basis for the glycosphingolipid-binding specificity of \u03b1-synuclein: Key role of tyrosine 39 in membrane insertion. J. Mol. Biol. 408(4), 654\u2013669 (2011).","journal-title":"J. Mol. Biol."},{"issue":"10","key":"94148_CR33","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1016\/j.bbamem.2011.06.017","volume":"1808","author":"J Fantini","year":"2011","unstructured":"Fantini, J., Carlus, D. & Yahi, N. The fusogenic Tilted peptide (67\u201378) of \u03b1-synuclein is a cholesterol binding domain. Biochim. Biophys. Acta 1808(10), 2343\u20132351 (2011).","journal-title":"Biochim. Biophys. Acta"},{"issue":"28","key":"94148_CR34","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1021\/bi500373k","volume":"53","author":"C Di Scala","year":"2014","unstructured":"Di Scala, C. et al. Interaction of Alzheimer\u2019s \u03b2-amyloid peptides with cholesterol: mechanistic insights into amyloid pore formation. Biochemistry 53(28), 4489\u20134502 (2014).","journal-title":"Biochemistry"},{"key":"94148_CR35","doi-asserted-by":"crossref","unstructured":"Fantini, J. & Yahi, N. The driving force of alpha-synuclein insertion and amyloid channel formation in the plasma membrane of neural cells: Key role of ganglioside-and cholesterol-binding domains. In Lipid-Mediated Protein Signal 15\u201326 (2013).","DOI":"10.1007\/978-94-007-6331-9_2"},{"issue":"2","key":"94148_CR36","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3390\/ijms24021760","volume":"24","author":"F Azzaz","year":"2023","unstructured":"Azzaz, F. et al. AmyP53 prevents the formation of neurotoxic \u03b2-Amyloid oligomers through an unprecedent mechanism of interaction with gangliosides: Insights for Alzheimer\u2019s disease therapy. Int. J. Mol. Sci. 24(2), 1760 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"94148_CR37","doi-asserted-by":"publisher","first-page":"183536","DOI":"10.1016\/j.bbamem.2020.183536","volume":"1863","author":"G Musteikyt\u0117","year":"2021","unstructured":"Musteikyt\u0117, G. et al. Interactions of \u03b1-synuclein oligomers with lipid membranes. Biochim. Biophys. Acta BBA Biomembr. 1863(4), 183536 (2021).","journal-title":"Biochim. Biophys. Acta BBA Biomembr."},{"key":"94148_CR38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.neuint.2017.12.014","volume":"119","author":"M Suzuki","year":"2018","unstructured":"Suzuki, M. et al. Pathological role of lipid interaction with \u03b1-synuclein in Parkinson\u2019s disease. Neurochem. Int. 119, 97\u2013106 (2018).","journal-title":"Neurochem. Int."},{"issue":"8","key":"94148_CR39","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1002\/pro.3906","volume":"29","author":"J Fantini","year":"2020","unstructured":"Fantini, J., Chahinian, H. & Yahi, N. Progress toward Alzheimer\u2019s disease treatment: leveraging the Achilles\u2019 heel of A\u03b2 oligomers?. Protein Sci. 29(8), 1748\u20131759 (2020).","journal-title":"Protein Sci."},{"issue":"8","key":"94148_CR40","doi-asserted-by":"publisher","first-page":"e104751","DOI":"10.1371\/journal.pone.0104751","volume":"9","author":"N Yahi","year":"2014","unstructured":"Yahi, N. & Fantini, J. Deciphering the glycolipid code of Alzheimer\u2019s and Parkinson\u2019s amyloid proteins allowed the creation of a universal ganglioside-binding peptide. PloS One 9(8), e104751 (2014).","journal-title":"PloS One"},{"issue":"8","key":"94148_CR41","doi-asserted-by":"publisher","first-page":"183233","DOI":"10.1016\/j.bbamem.2020.183233","volume":"1862","author":"K Matsuzaki","year":"2020","unstructured":"Matsuzaki, K. A\u03b2\u2013ganglioside interactions in the pathogenesis of Alzheimer\u2019s disease. Biochim. Biophys. Acta BBa Biomembr. 1862(8), 183233 (2020).","journal-title":"Biochim. Biophys. Acta BBa Biomembr."},{"issue":"2","key":"94148_CR42","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1006\/abbi.2001.2304","volume":"388","author":"T Ariga","year":"2001","unstructured":"Ariga, T. et al. Characterization of High-Affinity binding between gangliosides and amyloid \u03b2-Protein. Arch. Biochem. Biophys. 388(2), 225\u2013230 (2001).","journal-title":"Arch. Biochem. Biophys."},{"issue":"1","key":"94148_CR43","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jmb.2010.01.046","volume":"397","author":"E Di Pasquale","year":"2010","unstructured":"Di Pasquale, E. et al. Altered ion channel formation by the Parkinson\u2019s-disease-linked E46K mutant of \u03b1-synuclein is corrected by GM3 but not by GM1 gangliosides. J. Mol. Biol. 397(1), 202\u2013218 (2010).","journal-title":"J. Mol. Biol."},{"issue":"7","key":"94148_CR44","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1021\/bi061749a","volume":"46","author":"Z Martinez","year":"2007","unstructured":"Martinez, Z. et al. GM1 specifically interacts with \u03b1-synuclein and inhibits fibrillation. Biochemistry 46(7), 1868\u20131877 (2007).","journal-title":"Biochemistry"},{"issue":"10","key":"94148_CR45","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.bbapap.2018.07.004","volume":"1866","author":"R Gaspar","year":"2018","unstructured":"Gaspar, R. et al. Ganglioside lipids accelerate \u03b1-synuclein amyloid formation. Biochim. Biophys. Acta BBA Proteins Proteom. 1866(10), 1062\u20131072 (2018).","journal-title":"Biochim. Biophys. Acta BBA Proteins Proteom."},{"key":"94148_CR46","doi-asserted-by":"publisher","first-page":"106934","DOI":"10.1016\/j.bpc.2022.106934","volume":"293","author":"S Fridolf","year":"2023","unstructured":"Fridolf, S. et al. Ganglioside GM3 stimulates lipid-protein co-assembly in \u03b1-synuclein amyloid formation. Biophys. Chem. 293, 106934 (2023).","journal-title":"Biophys. Chem."},{"issue":"21","key":"94148_CR47","doi-asserted-by":"publisher","first-page":"13383","DOI":"10.3390\/ijms232113383","volume":"23","author":"C Di Scala","year":"2022","unstructured":"Di Scala, C. et al. AmyP53, a therapeutic peptide candidate for the treatment of Alzheimer\u2019s and Parkinson\u2019s disease: Safety, stability, pharmacokinetics parameters and nose-to brain delivery. Int. J. Mol. Sci. 23(21), 13383 (2022).","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"94148_CR48","doi-asserted-by":"publisher","first-page":"11550","DOI":"10.3390\/ijms222111550","volume":"22","author":"A El-Battari","year":"2021","unstructured":"El-Battari, A. et al. Gene therapy strategy for Alzheimer\u2019s and Parkinson\u2019s diseases aimed at preventing the formation of neurotoxic oligomers in SH-SY5Y cells. Int. J. Mol. Sci. 22(21), 11550 (2021).","journal-title":"Int. J. Mol. Sci."},{"issue":"36","key":"94148_CR49","doi-asserted-by":"publisher","first-page":"18098","DOI":"10.1073\/pnas.1908051116","volume":"116","author":"A Flores","year":"2019","unstructured":"Flores, A. et al. Gangliosides interact with synaptotagmin to form the high-affinity receptor complex for botulinum neurotoxin B. Proc. Natl. Acad. Sci. U. S. A. 116(36), 18098\u201318108 (2019).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"94148_CR50","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0006-291X(74)80442-0","volume":"61","author":"DW Urry","year":"1974","unstructured":"Urry, D. W. et al. Circular dichroism and absorption of the polytetrapeptide of Elastin: A polymer model for the beta-turn. Biochem. Biophys. Res. Commun. 61(4), 1427\u20131433 (1974).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"17","key":"94148_CR51","doi-asserted-by":"publisher","first-page":"9864","DOI":"10.3390\/ijms23179864","volume":"23","author":"A Henriques","year":"2022","unstructured":"Henriques, A. et al. Alpha-synuclein: The spark that flames dopaminergic neurons, in vitro and in vivo evidence. Int. J. Mol. Sci. 23(17), 9864 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"94148_CR52","doi-asserted-by":"crossref","unstructured":"Roux, S., Sabl\u00e9, E. & Porsolt, R. D. Primary observation (Irwin) test in rodents for assessing acute toxicity of a test agent and its effects on behavior and physiological function. Curr. Protoc. Pharmacol. (2005).","DOI":"10.1002\/0471141755.ph1010s27"},{"issue":"10","key":"94148_CR53","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1177\/28.10.6775025","volume":"28","author":"GA Ackerman","year":"1980","unstructured":"Ackerman, G. A., Wolken, K. W. & Gelder, F. B. Surface distribution of monosialoganglioside GM1 on human blood cells and the effect of exogenous GM1 and neuraminidase on cholera toxin surface labeling. A quantitative immunocytochemical study. J. Histochem. Cytochem. 28(10), 1100\u20131112 (1980).","journal-title":"J. Histochem. Cytochem."},{"issue":"2","key":"94148_CR54","first-page":"387","volume":"73","author":"S Ando","year":"1973","unstructured":"Ando, S. & YAMAKAWA, T. Separation of Polar glycolipids from human red blood cells with special reference to blood Group-A activit. J. Biochem. 73(2), 387\u2013396 (1973).","journal-title":"J. Biochem."},{"issue":"5","key":"94148_CR55","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/mutage\/gei045","volume":"20","author":"C Thompson","year":"2005","unstructured":"Thompson, C. et al. Modified bacterial mutation test procedures for evaluation of peptides and amino acid-containing material. Mutagenesis 20(5), 345\u2013350 (2005).","journal-title":"Mutagenesis"},{"issue":"14","key":"94148_CR56","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2165\/00003088-200342140-00004","volume":"42","author":"DR Guay","year":"2003","unstructured":"Guay, D. R. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin. Pharmacokinet. 42(14), 1243\u20131285 (2003).","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"94148_CR57","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1517\/14712598.2016.1165661","volume":"16","author":"RE Kontermann","year":"2016","unstructured":"Kontermann, R. E. Half-life extended biotherapeutics. Expert Opin. Biol. Ther. 16(7), 903\u2013915 (2016).","journal-title":"Expert Opin. Biol. Ther."},{"key":"94148_CR58","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jconrel.2019.02.016","volume":"301","author":"R Zaman","year":"2019","unstructured":"Zaman, R. et al. Current strategies in extending half-lives of therapeutic proteins. J. Control Release. 301, 176\u2013189 (2019).","journal-title":"J. Control Release"},{"issue":"5","key":"94148_CR59","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1039\/C0MD00111B","volume":"1","author":"L Pollaro","year":"2010","unstructured":"Pollaro, L. & Heinis, C. Strategies to prolong the plasma residence time of peptide drugs. MedChemComm 1(5), 319\u2013324 (2010).","journal-title":"MedChemComm"},{"issue":"4","key":"94148_CR60","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3988\/jcn.2011.7.4.215","volume":"7","author":"MJ Park","year":"2011","unstructured":"Park, M. J. et al. Elevated levels of \u03b1-synuclein oligomer in the cerebrospinal fluid of drug-na\u00efve patients with Parkinson\u2019s disease. J. Clin. Neurol. 7(4), 215\u2013222 (2011).","journal-title":"J. Clin. Neurol."},{"issue":"20","key":"94148_CR61","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","volume":"75","author":"T Tokuda","year":"2010","unstructured":"Tokuda, T. et al. Detection of elevated levels of \u03b1-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75(20), 1766\u20131772 (2010).","journal-title":"Neurology"},{"issue":"2","key":"94148_CR62","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/0896-6273(95)90040-3","volume":"15","author":"JM George","year":"1995","unstructured":"George, J. M. et al. Characterization of a novel protein regulated during the critical period for song learning in the zebra Finch. Neuron 15(2), 361\u2013372 (1995).","journal-title":"Neuron"},{"issue":"1","key":"94148_CR63","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","volume":"25","author":"A Abeliovich","year":"2000","unstructured":"Abeliovich, A. et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25(1), 239\u2013252 (2000).","journal-title":"Neuron"},{"issue":"20","key":"94148_CR64","doi-asserted-by":"publisher","first-page":"8797","DOI":"10.1523\/JNEUROSCI.22-20-08797.2002","volume":"22","author":"DE Cabin","year":"2002","unstructured":"Cabin, D. E. et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22(20), 8797\u20138807 (2002).","journal-title":"J. Neurosci."},{"issue":"1\u20132","key":"94148_CR65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11010-008-0008-y","volume":"326","author":"MY Golovko","year":"2009","unstructured":"Golovko, M. Y. et al. The role of alpha-synuclein in brain lipid metabolism: A downstream impact on brain inflammatory response. Mol. Cell. Biochem. 326(1\u20132), 55\u201366 (2009).","journal-title":"Mol. Cell. Biochem."},{"issue":"4","key":"94148_CR66","doi-asserted-by":"publisher","first-page":"509","DOI":"10.55782\/ane-2008-1717","volume":"68","author":"SJ Lee","year":"2008","unstructured":"Lee, S. J., Jeon, H. & Kandror, K. V. Alpha-synuclein is localized in a subpopulation of rat brain synaptic vesicles. Acta Neurobiol. Exp. 68(4), 509\u2013515 (2008).","journal-title":"Acta Neurobiol. Exp."},{"issue":"9","key":"94148_CR67","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1523\/JNEUROSCI.20-09-03214.2000","volume":"20","author":"DD Murphy","year":"2000","unstructured":"Murphy, D. D. et al. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20(9), 3214\u20133220 (2000).","journal-title":"J. Neurosci."},{"issue":"1","key":"94148_CR68","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neuron.2009.12.023","volume":"65","author":"VM Nemani","year":"2010","unstructured":"Nemani, V. M. et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65(1), 66\u201379 (2010).","journal-title":"Neuron"},{"issue":"5651","key":"94148_CR69","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1126\/science.1090439","volume":"302","author":"TF Outeiro","year":"2003","unstructured":"Outeiro, T. F. & Lindquist, S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302(5651), 1772\u20131775 (2003).","journal-title":"Science"},{"issue":"5651","key":"94148_CR70","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1126\/science.1090389","volume":"302","author":"S Willingham","year":"2003","unstructured":"Willingham, S. et al. Yeast genes that enhance the toxicity of a mutant Huntingtin fragment or alpha-synuclein. Science 302(5651), 1769\u20131772 (2003).","journal-title":"Science"},{"issue":"1","key":"94148_CR71","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0165-3806(96)00210-6","volume":"99","author":"GS Withers","year":"1997","unstructured":"Withers, G. S. et al. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res. Dev. Brain Res. 99(1), 87\u201394 (1997).","journal-title":"Brain Res. Dev. Brain Res."},{"issue":"4","key":"94148_CR72","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jchemneu.2010.12.001","volume":"42","author":"F Cheng","year":"2011","unstructured":"Cheng, F., Vivacqua, G. & Yu, S. The role of alpha-synuclein in neurotransmission and synaptic plasticity. J. Chem. Neuroanat. 42(4), 242\u2013248 (2011).","journal-title":"J. Chem. Neuroanat."},{"issue":"23","key":"94148_CR73","doi-asserted-by":"publisher","first-page":"11113","DOI":"10.1073\/pnas.1903049116","volume":"116","author":"J Sun","year":"2019","unstructured":"Sun, J. et al. Functional Cooperation of \u03b1-synuclein and VAMP2 in synaptic vesicle recycling. Proc. Natl. Acad. Sci. 116(23), 11113\u201311115 (2019).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"94148_CR74","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fnins.2019.00028","volume":"13","author":"M Huang","year":"2019","unstructured":"Huang, M. et al. \u03b1-Synuclein: A multifunctional player in exocytosis, endocytosis, and vesicle recycling. Front. NeuroSci. 13, 28 (2019).","journal-title":"Front. NeuroSci."},{"issue":"2","key":"94148_CR75","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.tins.2022.11.007","volume":"46","author":"M Sharma","year":"2023","unstructured":"Sharma, M. & Burr\u00e9, J. \u03b1-Synuclein in synaptic function and dysfunction. Trends Neurosci. 46(2), 153\u2013166 (2023).","journal-title":"Trends Neurosci."},{"issue":"4","key":"94148_CR76","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.plipres.2010.05.004","volume":"49","author":"V Ruip\u00e9rez","year":"2010","unstructured":"Ruip\u00e9rez, V., Darios, F. & Davletov, B. Alpha-synuclein, lipids and Parkinson\u2019s disease. Prog. Lipid Res. 49(4), 420\u2013428 (2010).","journal-title":"Prog. Lipid Res."},{"issue":"4","key":"94148_CR77","doi-asserted-by":"publisher","first-page":"292","DOI":"10.5607\/en.2014.23.4.292","volume":"23","author":"D Snead","year":"2014","unstructured":"Snead, D. & Eliezer, D. Alpha-synuclein function and dysfunction on cellular membranes. Exp. Neurobiol. 23(4), 292 (2014).","journal-title":"Exp. Neurobiol."},{"key":"94148_CR78","doi-asserted-by":"publisher","first-page":"105086","DOI":"10.1016\/j.nbd.2020.105086","volume":"146","author":"ST Kumar","year":"2020","unstructured":"Kumar, S. T. et al. How specific are the conformation-specific \u03b1-synuclein antibodies? Characterization and validation of 16 \u03b1-synuclein conformation-specific antibodies using well-characterized preparations of \u03b1-synuclein monomers, fibrils and oligomers with distinct structures and morphology. Neurobiol. Dis. 146, 105086 (2020).","journal-title":"Neurobiol. Dis."},{"issue":"9 Pt B","key":"94148_CR79","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.bbamem.2017.05.017","volume":"1859","author":"PV Escrib\u00e1","year":"2017","unstructured":"Escrib\u00e1, P. V. Membrane-lipid therapy: A historical perspective of membrane-targeted therapies\u2014From lipid bilayer structure to the pathophysiological regulation of cells. Biochim. Biophys. Acta Biomembr. 1859(9 Pt B), 1493\u20131506 (2017).","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"6","key":"94148_CR80","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1073\/pnas.1620159114","volume":"114","author":"A Pineda","year":"2017","unstructured":"Pineda, A. & Burr\u00e9, J. Modulating membrane binding of \u03b1-synuclein as a therapeutic strategy. Proc. Natl. Acad. Sci. U. S. A. 114(6), 1223\u20131225 (2017).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"94148_CR81","doi-asserted-by":"crossref","unstructured":"Inci, O. K. et al. Gangliosides as therapeutic targets for neurodegenerative diseases. J. Lipids 4530255 (2024).","DOI":"10.1155\/2024\/4530255"},{"key":"94148_CR82","doi-asserted-by":"publisher","first-page":"108797","DOI":"10.1016\/j.pharmthera.2025.108797","volume":"267","author":"J Fantini","year":"2025","unstructured":"Fantini, J. et al. Conformationally adaptive therapeutic peptides for diseases caused by intrinsically disordered proteins (IDPs). New paradigm for drug discovery: Target the target, not the arrow. Pharmacol. Ther. 267, 108797 (2025).","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"94148_CR83","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.bbadis.2015.11.012","volume":"1862","author":"C Di Scala","year":"2016","unstructured":"Di Scala, C. et al. Broad neutralization of calcium-permeable amyloid pore channels with a chimeric Alzheimer\/Parkinson peptide targeting brain gangliosides. Biochim. Biophys. Acta 1862(2), 213\u2013222 (2016).","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"94148_CR84","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1006\/jmbi.2001.5269","volume":"315","author":"E Jo","year":"2002","unstructured":"Jo, E. et al. Defective membrane interactions of Familial Parkinson\u2019s disease mutant A30P alpha-synuclein. J. Mol. Biol. 315(4), 799\u2013807 (2002).","journal-title":"J. Mol. Biol."},{"issue":"12","key":"94148_CR85","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1021\/jacs.6b05335","volume":"139","author":"M Robotta","year":"2017","unstructured":"Robotta, M. et al. Alpha-Synuclein disease mutations are structurally defective and locally affect membrane binding. J. Am. Chem. Soc. 139(12), 4254\u20134257 (2017).","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"94148_CR86","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bbamem.2011.07.032","volume":"1818","author":"CM Pfefferkorn","year":"2012","unstructured":"Pfefferkorn, C. M., Jiang, Z. & Lee, J. C. Biophysics of \u03b1-synuclein membrane interactions. Biochim. Biophys. Acta 1818(2), 162\u2013171 (2012).","journal-title":"Biochim. Biophys. Acta"},{"issue":"21","key":"94148_CR87","doi-asserted-by":"publisher","first-page":"21966","DOI":"10.1074\/jbc.M401076200","volume":"279","author":"B Nuscher","year":"2004","unstructured":"Nuscher, B. et al. Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: A thermodynamics study. J. Biol. Chem. 279(21), 21966\u201321975 (2004).","journal-title":"J. Biol. Chem."},{"issue":"27","key":"94148_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399402005392","volume":"4","author":"J Fantini","year":"2002","unstructured":"Fantini, J. et al. Lipid rafts: Structure, function and role in HIV, Alzheimer\u2019s and prion diseases. Expert Rev. Mol. Med. 4(27), 1\u201322 (2002).","journal-title":"Expert Rev. Mol. Med."},{"issue":"36","key":"94148_CR89","doi-asserted-by":"publisher","first-page":"31664","DOI":"10.1074\/jbc.M504894200","volume":"280","author":"S Kubo","year":"2005","unstructured":"Kubo, S. et al. A combinatorial code for the interaction of \u03b1-synuclein with membranes. J. Biol. Chem. 280(36), 31664\u201331672 (2005).","journal-title":"J. Biol. Chem."},{"key":"94148_CR90","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.neurobiolaging.2019.01.020","volume":"77","author":"M Dukhinova","year":"2019","unstructured":"Dukhinova, M. et al. Fresh evidence for major brain gangliosides as a target for the treatment of Alzheimer\u2019s disease. Neurobiol. Aging. 77, 128\u2013143 (2019).","journal-title":"Neurobiol. Aging"},{"issue":"34","key":"94148_CR91","doi-asserted-by":"publisher","first-page":"9220","DOI":"10.1523\/JNEUROSCI.2617-07.2007","volume":"27","author":"KM Danzer","year":"2007","unstructured":"Danzer, K. M. et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27(34), 9220\u20139232 (2007).","journal-title":"J. Neurosci."},{"issue":"1","key":"94148_CR92","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/jnc.12390","volume":"128","author":"C Di Scala","year":"2014","unstructured":"Di Scala, C. et al. Mechanism of cholesterol-assisted oligomeric channel formation by a short alzheimer \u03b2-amyloid peptide. J. Neurochem. 128(1), 186\u2013195 (2014).","journal-title":"J. Neurochem."},{"issue":"7","key":"94148_CR93","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/brain\/awy146","volume":"141","author":"JL Robinson","year":"2018","unstructured":"Robinson, J. L. et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 141(7), 2181\u20132193 (2018).","journal-title":"Brain"},{"issue":"1","key":"94148_CR94","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3233\/JPD-202323","volume":"11","author":"Y Compta","year":"2021","unstructured":"Compta, Y. & Revesz, T. Neuropathological and biomarker findings in Parkinson\u2019s disease and Alzheimer\u2019s disease: From protein aggregates to synaptic dysfunction. J. Parkinsons Dis. 11(1), 107\u2013121 (2021).","journal-title":"J. Parkinsons Dis."},{"issue":"3","key":"94148_CR95","doi-asserted-by":"publisher","first-page":"fcab180","DOI":"10.1093\/braincomms\/fcab180","volume":"3","author":"R Biundo","year":"2021","unstructured":"Biundo, R. et al. The contribution of beta-amyloid to dementia in lewy body diseases: A 1-year follow-up study. Brain Commun. 3(3), fcab180 (2021).","journal-title":"Brain Commun."},{"key":"94148_CR96","doi-asserted-by":"publisher","first-page":"1153839","DOI":"10.3389\/fmolb.2023.1153839","volume":"10","author":"JR Kim","year":"2023","unstructured":"Kim, J. R. Oligomerization by co-assembly of \u03b2-amyloid and \u03b1-synuclein. Front. Mol. Biosci. 10, 1153839 (2023).","journal-title":"Front. Mol. Biosci."},{"key":"94148_CR97","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cbpa.2021.05.006","volume":"64","author":"HA Lashuel","year":"2021","unstructured":"Lashuel, H. A. Rethinking protein aggregation and drug discovery in neurodegenerative diseases: Why we need to embrace complexity? Curr. Opin. Chem. Biol. 64, 67\u201375 (2021).","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"1","key":"94148_CR98","doi-asserted-by":"publisher","first-page":"28781","DOI":"10.1038\/srep28781","volume":"6","author":"C Di Scala","year":"2016","unstructured":"Di Scala, C. et al. Common molecular mechanism of amyloid pore formation by Alzheimer\u2019s \u03b2-amyloid peptide and \u03b1-synuclein. Sci. Rep. 6(1), 28781 (2016).","journal-title":"Sci. Rep."},{"issue":"10","key":"94148_CR99","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1002\/jps.21317","volume":"97","author":"NJ Waters","year":"2008","unstructured":"Waters, N. J. et al. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J. Pharm. Sci. 97(10), 4586\u20134595 (2008).","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"94148_CR100","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey, W., Dalke, A. & Schulten, K. VMD: Visual molecular dynamics. J. Mol. Graph. 14(1), 33\u201338 (1996).","journal-title":"J. Mol. Graph."},{"issue":"27","key":"94148_CR101","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1002\/jcc.23702","volume":"35","author":"EL Wu","year":"2014","unstructured":"Wu, E. L. et al. CHARMM-GUI membrane builder toward realistic biological membrane simulations. J. Comput. Chem. 35(27), 1997\u20132004 (2014).","journal-title":"J. Comput. Chem."},{"issue":"11","key":"94148_CR102","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/jcc.20945","volume":"29","author":"S Jo","year":"2008","unstructured":"Jo, S. et al. CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 29(11), 1859\u20131865 (2008).","journal-title":"J. Comput. Chem."},{"issue":"16","key":"94148_CR103","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/jcc.20289","volume":"26","author":"JC Phillips","year":"2005","unstructured":"Phillips, J. C. et al. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26(16), 1781\u20131802 (2005).","journal-title":"J. Comput. Chem."},{"issue":"1","key":"94148_CR104","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nmeth.4067","volume":"14","author":"J Huang","year":"2017","unstructured":"Huang, J. et al. CHARMM36m: An improved force field for folded and intrinsically disordered proteins. Nat. Methods 14(1), 71\u201373 (2017).","journal-title":"Nat. Methods"},{"issue":"2","key":"94148_CR105","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.colsurfb.2009.07.043","volume":"74","author":"G Thakur","year":"2009","unstructured":"Thakur, G., Micic, M. & Leblanc, R. M. Surface chemistry of Alzheimer\u2019s disease: A Langmuir monolayer approach. Colloids Surf. B 74(2), 436\u2013456 (2009).","journal-title":"Colloids Surf. B"},{"key":"94148_CR106","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-1-4939-6875-6_2","volume":"1583","author":"C Di Scala","year":"2017","unstructured":"Di Scala, C. & Fantini, J. Hybrid in silico\/in vitro approaches for the identification of functional cholesterol-binding domains in membrane proteins. Methods Mol. Biol. 1583, 7\u201319 (2017).","journal-title":"Methods Mol. Biol."}],"updated-by":[{"DOI":"10.1038\/s41598-025-07762-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94148-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94148-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94148-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:02:43Z","timestamp":1751544163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94148-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94148"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94148-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-025-07762-4","URL":"https:\/\/doi.org\/10.1038\/s41598-025-07762-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.Y. and J.F. are co-inventors of the AmyP53 peptide (patent Application EP15709163.8\u00a0A), currently under development for the treatment of Alzheimer\u2019s and Parkinson\u2019s diseases by the AmyPore company. H.C. is president of the Ethics and Scientific Committee of AmyPore. A.A. is the project leader of AmyPore. F.A. does not have any conflict of interest. All other authors have no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9144"}}